Australia markets close in 1 hour 55 minutes

Allakos Inc. (ALLK)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
4.5500-0.0600 (-1.30%)
At close: 04:00PM EDT
4.5000 -0.05 (-1.10%)
After hours: 07:56PM EDT
Full screen
Loading interactive chart…
  • Motley Fool

    Why Allakos Stock Was Heating Up Today

    Although Allakos reported a net loss of $43 million in the fourth quarter of 2022, investors were more concerned with the progress of the company's clinical pipeline. More specifically, Allakos reaffirmed today that it expects to report trial results from a pair of ongoing mid-stage studies for its lead compound, lirentelimab, in the second half of 2023. The monoclonal antibody is presently in a phase 2 trial as a treatment for atopic dermatitis and a phase 2b trial for chronic spontaneous urticaria (hives).

  • GlobeNewswire

    Allakos Provides Business Update and Reports Fourth Quarter and Full Year 2022 Financial Results

    SAN CARLOS, Calif., March 06, 2023 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing antibodies for the treatment of allergic, inflammatory and proliferative diseases, today provided a business update and reported financial results for the fourth quarter and full year ended December 31, 2022. The Company’s most advanced antibodies are lirentelimab (AK002) and AK006. Recent Allakos Events Initiated a Phase 2b randomized, double-blind, placebo-cont

  • Simply Wall St.

    Is Allakos Inc. (NASDAQ:ALLK) Expensive For A Reason? A Look At Its Intrinsic Value

    How far off is Allakos Inc. ( NASDAQ:ALLK ) from its intrinsic value? Using the most recent financial data, we'll take...